Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Mar 04, 2022 4:01pm EST
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 42nd Annual Virtual Healthcare Conference Mar 02, 2022 8:00am EST
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress Feb 28, 2022 4:05pm EST
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022 Feb 17, 2022 4:01pm EST
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Feb 07, 2022 4:01pm EST
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm Jan 26, 2022 4:30pm EST
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis Jan 24, 2022 11:13am EST
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference Jan 10, 2022 8:30am EST
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 07, 2022 4:01pm EST
